Sugi Predict

Sugi Predict / Compounds / SCHEMBL1850804

SCHEMBL1850804

SCHEMBL1850804

C[C](C(=O)N(C)C)c1cc2ccccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 2/20 0.59
▸ KDM4E B2RXH2 3/20 0.57
▸ MAPT P10636 1/20 0.57
▸ DAO P14920 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ SRD5A2 P31213 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ HTR2C P28335 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ PDGFRB P09619 3/20 0.51
▸ PDGFRA P16234 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ EGFR P00533 2/20 0.49
▸ PIK3CA P42336 2/20 0.49
▸ FGFR1 P11362 1/20 0.49
▸ IDO1 P14902 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1849662 0.85 FLT3 (0.61) FLT3KDM4EMAPTDAOHPGD
SCHEMBL3993112 0.85 PDGFRB (0.53) FLT3KDM4EMAPTDAOHPGD
SCHEMBL4001756 0.85 KDM4E (0.55) FLT3KDM4EMAPTDAOHPGD
SCHEMBL3993301 0.83 FLT3 (0.54) FLT3KDM4EMAPTDAOHPGD
SCHEMBL1850844 0.83 FLT3 (0.57) FLT3KDM4EMAPTDAOHPGD
SCHEMBL1854127 0.81 KDM4E (0.68) FLT3KDM4EMAPTDAOHPGD
SCHEMBL378260 0.81 FLT3 (0.65) FLT3KDM4EMAPTDAOHPGD
SCHEMBL29595772 0.81 FLT3 (0.65) FLT3KDM4EMAPTDAOHPGD
SCHEMBL1852619 0.81 FLT3 (0.48) FLT3KDM4EMAPTDAOHPGD
Hydrochloric Acid SCHEMBL35211567 0.80 FLT3 (0.62) FLT3KDM4EMAPTDAOHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA FLT3 347/4885KDM4E 2802/4885MAPT 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.